Genetic Technologies Ltd (ASX: GTG) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Genetic Technologies Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$15.20 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
132.22 million
Earnings per share
-0.008
Dividend per share
N/A
Year To Date Return
-14.81%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Genetic Technologies Ltd (ASX: GTG)
Latest News
⏸️ Investing
Market wipeout: Stocks crushed in $24 billion rush for the exits
⏸️ Investing
4 stocks soaring on the ASX today
⏸️ Investing
Genetic Technologies Limited soars 30%: Here's why
GTG ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Genetic Technologies Ltd
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
GTG Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 24 Apr 2024 | $0.12 | $-0.01 | -8.00% | 1,413 | $0.12 | $0.12 | $0.12 |
| 23 Apr 2024 | $0.13 | $0.01 | 8.33% | 120,901 | $0.12 | $0.13 | $0.12 |
| 22 Apr 2024 | $0.12 | $-0.02 | -14.29% | 476,021 | $0.13 | $0.13 | $0.12 |
| 19 Apr 2024 | $0.14 | $-0.04 | -22.86% | 395,611 | $0.14 | $0.15 | $0.13 |
| 18 Apr 2024 | $0.18 | $0.00 | 0.00% | 6,219 | $0.17 | $0.18 | $0.17 |
| 17 Apr 2024 | $0.17 | $0.01 | 6.06% | 28 | $0.17 | $0.17 | $0.17 |
| 16 Apr 2024 | $0.17 | $0.00 | 0.00% | 63,460 | $0.17 | $0.17 | $0.17 |
| 15 Apr 2024 | $0.17 | $-0.01 | -5.71% | 11,148 | $0.17 | $0.17 | $0.17 |
| 12 Apr 2024 | $0.18 | $0.02 | 12.50% | 62,078 | $0.17 | $0.18 | $0.17 |
| 11 Apr 2024 | $0.16 | $-0.02 | -11.43% | 330,851 | $0.18 | $0.19 | $0.16 |
| 10 Apr 2024 | $0.18 | $0.04 | 29.63% | 270,812 | $0.14 | $0.19 | $0.14 |
| 09 Apr 2024 | $0.14 | $0.00 | 0.00% | 574 | $0.14 | $0.14 | $0.14 |
| 08 Apr 2024 | $0.14 | $-0.01 | -6.90% | 5,991 | $0.15 | $0.15 | $0.14 |
| 05 Apr 2024 | $0.15 | $0.00 | 0.00% | 1,498 | $0.14 | $0.15 | $0.14 |
| 04 Apr 2024 | $0.15 | $0.00 | 0.00% | 7,154 | $0.13 | $0.15 | $0.13 |
| 03 Apr 2024 | $0.14 | $0.00 | 0.00% | 39,402 | $0.14 | $0.14 | $0.14 |
| 02 Apr 2024 | $0.14 | $0.00 | 0.00% | 102,952 | $0.14 | $0.14 | $0.13 |
| 28 Mar 2024 | $0.14 | $0.02 | 16.00% | 7,391 | $0.13 | $0.14 | $0.13 |
| 27 Mar 2024 | $0.13 | $-0.02 | -14.29% | 38,303 | $0.13 | $0.13 | $0.13 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 06 Mar 2024 | Peter Rubinstein | Buy | 617,209 | $80,315 |
On-market trade. average price
|
| 21 Dec 2023 | Nicholas (Nick) Burrows | Expiry | 5,000,000 | $750,000 |
As advised by the company. Expired
|
| 21 Dec 2023 | Lindsay Wakefield | Expiry | 5,000,000 | $750,000 |
As advised by the company. Expired
|
| 21 Dec 2023 | Jerzy (George) Muchnicki | Expiry | 57,500,000 | $8,625,000 |
As advised by the company. Expired, As per announcement on 27-12-2023
|
| 21 Dec 2023 | Peter Rubinstein | Expiry | 57,500,000 | $8,625,000 |
As advised by the company. Expired
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Lindsay Peter Wakefield | Non-Executive Director | Sep 2014 |
Dr Wakefield started Safetech Pty Ltd in 1985 and over the next 25 years, Safetech became a force in the Australian material handling and lifting equipment market, designing and manufacturing a range of industrial products. In 1993, he left medicine to become the full time CEO of Safetech. In 2006, Safetech was awarded the Telstra Australian National Business of the Year. In 2013, Safetech merged and ultimately acquired Tiemen Materials Handling. Dr Wakefield continues as the CEO of Safetech. It is Australia's largest manufacturer and supplier of dock equipment, freight hoists and custom lifting solutions. Safetech employs approximately 100 people. Dr Wakefield has been a biotech investor for more than 20 years
|
| Dr Jerzy (George) Muchnicki | Executive Director | Jan 2018 |
Dr Muchnicki acted as Interim Chief Executive Officer from September 2019 till the appointment of Mr. Simon Morriss to the role. For the past 14 years, he has been involved in commercialization and funding R&D in the biotechnology sector from gene silencing to regenerative medicine. Dr Muchnicki brings with him commercial and medical skills, including broad interests in software development, blockchain and sustainable building materials. He is a co-founder and Non-Executive Director of Speed Panel Holdings a world leader in fire rated and acoustic wall solutions. He is also the co-founder of Candlebets, a software development company that is creating blockchain enabled platforms for the gaming industry.
|
| Mr Peter Irwin Rubinstein | Non-Executive ChairmanNon-Executive Director | Jan 2018 |
Mr Rubinstein has over 20 years' experience in early-stage technology commercialization through to public listings on the ASX. He is a lawyer, having worked at a national firm prior to moving in-house at Montech, the commercial arm of Monash University. Mr. Rubinstein has had exposure to the creation, launch and management of a diverse range of technology companies in biotech, digital payments and renewable energy.
|
| Ms Kathryn Andrews | Chief Financial OfficerCompany Secretary | Mar 2024 |
-
|
| Mr Simon Morriss | Chief Executive Officer | Feb 2021 |
-
|
| Carl Stubbings | Chief Commercial Officer |
-
|
|
| Simon Morriss | Chief Executive Officer |
-
|
|
| Simon Morriss | Chief Executive Officer |
-
|
|
| Kevin Camilleri | Chief Executive Officer of EasyDNA |
-
|
|
| Kathryn Andrews | Chief Financial OfficerCompany Secretary |
-
|
|
| Richard Allman | Scientific Advisor former Chief Scientific Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 8,119,123,510 | 70.35% |
| Mr Warwick Wright | 217,500,000 | 1.88% |
| Mjgd Nominees Pty Ltd | 200,849,309 | 1.74% |
| Doma 193 Pty Ltd <Doma 193 A/C> | 144,551,379 | 1.25% |
| Rip Opportunities Pty Ltd <Pir Super Fund A/C> | 124,999,999 | 1.08% |
| Irwin Biotech Nominees Pty Ltd <Bioa A/C> | 75,849,310 | 0.66% |
| Ap 300 Pty Ltd <Ap Invest A/C> | 48,040,000 | 0.42% |
| Monument Hill Pty Ltd | 42,000,001 | 0.36% |
| Miss Susan Spiteri | 40,142,778 | 0.35% |
| Mrs Helen Kamer & Mr Benjamin Kamer <Kamer Super Fund A/C> | 40,000,000 | 0.35% |
| Mr Lei Da Tao | 38,000,000 | 0.33% |
| Bnp Paribas Nominees Pty Ltd Acf Clearstream | 35,043,531 | 0.30% |
| Aquasafe Investments Pty Ltd <White Superfund A/C> | 30,608,028 | 0.27% |
| Whalecorp Pty Ltd <Whalecorp Pty Ltd S/F A/C> | 30,000,000 | 0.26% |
| Miss Beverley Susan Mccain | 28,000,000 | 0.24% |
| Mr John Christopolous <Chrisand Family A/C> | 27,000,000 | 0.23% |
| Mr Bill Gianoulas | 25,000,000 | 0.22% |
| Mr Michael Battley | 24,221,459 | 0.21% |
| Citicorp Nominees Pty Limited | 23,257,576 | 0.20% |
| Mr Can Odabas | 23,000,000 | 0.20% |
